Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 5, 2006, Pages 627-641

  Huang, Yadong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid; Alzheimer's disease; Apolipoprotein E4; Mitochondrial dysfunction; Neurodegeneration; Proteolysis

Indexed keywords

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; TAU PROTEIN;

ALZHEIMER DISEASE; ASTROCYTE; EXPERIMENTAL MODEL; HOMEOSTASIS; HUMAN; LIPID METABOLISM; NERVE DEGENERATION; NEUROBIOLOGY; NEUROTOXICITY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; HUMANS; NEUROTOXINS; POLYMORPHISM, GENETIC;

EID: 33748607443     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (194)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population. Prevalence estimates using the 2000 census. Arch Neurol (2003) 60(8):1119-1122.
2. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron (1991) 6(4):487-498.
3. Jacobsen JS: Alzheimer's disease: An overview of current and emerging therapeutic strategies. Curr Top Med Chem (2002) 2(4):343-352.
4. Selkoe DJ: Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease. J Clin Invest (2002) 110(10):1375-1381.
5. Hardy J: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci (1997) 20(4):154-159.
6. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375(6534):754-760.
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 261(5123):921-923. One of the first reports to state apoE4 as a major risk factor for late onset AD.
8. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, Mayeux R: The apoE-ε4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. J Am Med Assoc (1998) 279(10):751-755.
9. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C et al: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology (1993) 43(8):1467-1472.
10. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science (1988) 240(4852):622-630.
11. Utermann G, Langenbeck U, Beisiegel U, Weber W: Genetics of the apolipoprotein E system in man. Am J Hum Genet (1980) 32(3):339-347.
12. Utermann G, Steinmetz A, Weber W: Genetic control of human apolipoprotein E polymorphism: Comparison of one- and two-dimensional techniques of isoprotein analysis. Hum Genet (1982) 60(4):344-351.
13. Zannis VI, Breslow JL: Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry (1981) 20(4):1033-1041.
14. Zannis VI, Just PW, Breslow JL: Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet (1981) 33(1):11-24.
15. Weisgraber KH, Rail SC Jr, Mahley RW: Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem (1981) 256(17):9077-9083.
16. Rail SC Jr, Weisgraber KH, Mahley RW: Human apolipoprotein E. The complete amino acid sequence. J Biol Chem (1982) 257(8):4171-4178.
17. Rail SC Jr, Weisgraber KH, Innerarity TL, Mahley RW: Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA (1982) 79(15):4696-4700.
18. Mahley RW, Rail SC Jr: Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (Eds), McGraw-Hill New York, NY, USA (2001):2835-2862.
19. Mahley RW, Ji Z-S: Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res (1999) 40(1):1-16.
20. Weisgraber KH: Apolipoprotein E: Structure-function relationships. Adv Protein Chem (1994) 45:249-302.
21. Huang Y, Mahley RW: Apolipoprotein E and human disease. In: Plasma Lipids and Their Role in Disease. Barter PJ, Rye K-A (Eds), Harwood Academic Publishers, Amsterdam, the Netherlands (1999):257-284.
22. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, Weisgraber KH: Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry (2000) 39(38):11657-11666. First in vitro demonstration that apoE4 is less stable than apoE2 and apoE3.
23. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA: Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem (1994) 269(35):22358-22365.
24. 255.
25. Xu Q, Brecht WJ, Weisgraber KH, Mahley RW, Huang Y: Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer. J Biol Chem (2004) 279(24):25511-25516. First demonstration that apoE4 domain interaction occurs in living cells, as determined by fluorescence resonance energy transfer.
26. Ye S, Huang Y, Müllendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW: Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc Natl Acad Sci USA (2005) 102(51):18700-18705. First in vitro demonstration that small-molecule compounds that disrupt apoE4 domain interaction can abolish apoE4 stimulation of Aβ production in neuronal cultures.
27. Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA (2006) 103(15):5644-5651. An excellent review of apoE4 as a causative factor and therapeutic target in AD.
28. 61 introduces the domain interaction into mouse apoE.
29. Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E. Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci (2004) 23(3):189-204.
30. Huang Y: Apolipoprotein E and Alzheimer disease. Neurology (2006) 66(Suppl 1):S79-S85. A detailed review on apoE and AD.
31. Mahley RW, Huang Y: Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol (1999) 10(3):207-217.
32. Weisgraber KH, Mahley RW: Human apolipoprotein E: The Alzheimer's disease connection. FASEB J (1996) 10(13):1485-1494.
33. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM: Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA (1985) 82(1):203-207.
34. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM: Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest (1985) 76(4):1501-1513.
35. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW: Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta (1987) 917(1):148-161.
36. Beffert U, Poirier J: Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann NY Acad Sci (1996) 777:166-174.
37. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W 2nd, Haase AT: Neuropathic-logical changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol (1991) 65(9):4759-4768.
38. Han SH, Einstein G, Weisgraber KH, Strittmatter WJ, Saunders AM, Pencak-Vance M, Roses AD, Schmechel DE: Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study. J Neuropathol Exp Neurol (1994) 53(5):535-544.
39. Bao F, Arai H, Matsushita S, Higuchi S, Sasaki H: Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. NeuroReport (1996) 7(11):1733-1739.
40. Metzger RE, LaDu MJ, Pan JB, Getz GS, Frail DE, Falduto MT: Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: Implications for Alzheimer's disease. J Neuropathol Exp Neurol (1996) 55(3):372-380.
41. Xu PT, Schmechel D, Qiu HL, Herbstreith M, Rothrock-Christian T, Eyster M, Roses AD, Gilbert JR: Slalylated human apolipoprotein E (apoE.) is preferentially associated with neuron-enriched cultures from apoE transgenic mice. Neurobiol Dis (1999) 6(1):63-75.
42. Dekroon RM, Armati PJ: Synthesis and processing of apolipoprotein E in human brain cultures. Glia (2001) 33(4):298-305.
43. Xu PT, Gilbert JR, Qiu HL, Ervin J, Rothrock-Christian TR, Hulette C, Schmechel DE: Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol (1999) 154(2):601-611.
44. Messmer-Joudrier S, Sagot Y, Mattenberger L, James RW, Kato AC: Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. Eur J Neurosci (1996) 8(12):2652-2661.
45. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y: Profile and regulation of apolipoprotein (apo) E expression in central nervous system in mice with targeting of green flourescent protein gene to the apoE locus. J Neurosci (2006) 26(19):4985-4994. Demonstration that apoE is expressed in CNS neurons in response to excitotoxic injury in mice by targeting green fluorescent protein gene to the apoE locus.
46. Beschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S: Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis (1999) 6(6):508-514.
47. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH: Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem (1987) 262(29):14352-14360.
48. LeBlanc AC, Poduslo JF: Regulation of apolipoprotein E gene expression after injury of the rat sciatic nerve. J Neurosci Res (1990) 25(2):162-171.
49. Skene JH, Shooter EM: Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci USA (1983) 80(13):4169-4173.
50. Muller HW, Gebicke-Harter PJ, Hangen DH, Shooter EM: A specific 37,000-Dalton protein that accumulates in regenerating but not in nonregenerating mammalian nerves. Science (1985) 228(4698):499-501.
51. Ignatius MJ, Gebicke-Harter PJ, Skene JH, Schilling JW, Weisgraber KH, Mahley RW, Shooter EM: Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA (1986) 83(4):1125-1129.
52. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ, Shooter EM: A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest (1989) 83(3):1015-1031.
53. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science (1994) 264(5160):850-852.
54. Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE: Effects of apolipoprotein E, β-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res (1992) 33(11):1677-1688.
55. Ignatius MJ, Shooter EM, Pitas RE, Mahley RW: Lipoprotein uptake by neuronal growth cones in vitro. Science (1987) 236(4804):959-962.
56. Chen Y, Lomnitski L, Michaelson DM, Shohami E: Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience (1997) 80(4):1255-1262.
57. Slooter AJ, Tang MX, van Duijn CM, Stern Y, Ott A, Bell K, Breteler MM, Van Broeckhoven C, Tatemichi TK, Tycko B, Hofman A et al: Apolipoprotein E ε4 and the risk of dementia with stroke. A population-based investigation. J Am Med Assoc (1997) 277(10):818-821
58. Poirier J, Baccichet A, Dea D, Gauthier S: Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience (1993) 55(1):81-90.
59. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD: Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol (1995) 136(2):107-122.
60. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW: Expression of human apolipoprotein E3 or E4 in the brains of apoE-/- mice: Isoform-specific effects on neurodegeneration. J Neurosci (1999) 19(12):4867-4880. A CNS apoE transgenic mouse model demonstrating that apoE has isoform-specific effects on neurodegeneration in vivo.
61. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L: Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience (2000) 97(2):207-210.
62. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L: Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J Neurosci (2002) 22(24):10539-10548.
63. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L: Isoform-specific effects of human apolipoprotein E on brain function revealed in apoE knockout mice: Increased susceptibility of females. Proc Natl Acad Sci USA (1998) 95(18):10914-10919. A CNS apoE transgenic mouse model demonstrating that apoE has isoform-specific effects on congnition in vivo.
64. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, Mucke L: Apolipoprotein E and cognitive performance. Nature (2000) 404(6776):352-354.
65. Raber J, Bongers G, LeFevour A, Buttini M, Mucke L: Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci (2002) 22(12):5204-5209.
66. Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM: Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. J Neurosci Res (2002) 68(3):331-336.
67. Corder EH, Saunders AM, Risen NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW et al: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7(2):180-184. First demonstration that apoE2 might be protective against AD.
68. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD: Apolipoprotein E-ε2 and Alzheimer's disease: Genotype influences pathologic phenotype. Neurology (1997) 48(2):515-519.
69. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 541(1):163-166.
70. Wisniewski T, Frangione B: Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett (1992) 135(2):235-238.
71. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA (1993) 90(5):1977-1981. One of the first reports to state apoE4 as a major risk factor for late-onset AD.
72. Nicoll JA, Roberts GW, Graham DI: Amyloid β-protein, apoE genotype and head injury. Ann NY Acad Sci (1996) 777:271-275.
73. Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, Saunders AM, Lai E, Martin ER, Vance JM, Oksenberg JR et al: Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet (2002) 70(3):708-717.
74. Kantarci OH, Hebrink DD, Achenbach SJ, Pittock SJ, Altintas A, Schaefer-Klein JL, Atkinson EJ, De Andrade M, McMurray CT, Rodriguez M, Weinshenker BG et al: Association of apoE polymorphisms with disease severity in MS is limited to women. Neurology (2004) 62(5):811-814.
75. Drory VE, Birnbaum M, Korczyn AD, Chapman J: Association of APOE ε4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci (2001) 190(1-2):17-20.
76. Moulard B, Sefiani A, Laamri A, Malafosse A, Camu W: Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: Evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci (1996) 139(Suppl):34-37.
77. Grehan S, Tse E, Taylor JM: Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci (2001) 21(3):812-822.
78. Basu SK, Brown MS, Ho YK, Havel RJ, Goldstein JL: Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci USA (1981) 78(12):7545-7549.
79. Xu Q, Li Y, Cyras C, Sanan DA, Cordell B: Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J Biol Chem (2000) 275(41):31770-31777.
80. Uchihara T, Duyckaerts C, He Y, Kobayashi K, Seilhean D, Amouyel P, Hauw JJ: ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci Lett (1995) 195(1):5-8.
81. Xu PT, Gilbert JR, Qiu HL, Rothrock-Christian T, Settles DL, Roses AD, Schmechel DE: Regionally specific neuronal expression of human apoE gene in transgenic mice. Neurosci Lett (1998) 246(2):65-68.
82. Harris FM, Tesseur I, Brecht WJ, Xu Q, Mullendorff K, Chang S, Wyss-Coray T, Mahley RW, Huang Y: Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J Biol Chem (2004) 279(5):3862-3868.
83. Van Dooren T, Muyllaert D, Borghgraef P, Cresens A, Devijver H, Van der Auwera I, Wera S, Dewachter I, Van Leuven F: Neuronal or glial expression of human apolipoprotein E4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am J Pathol (2006) 168(1):245-260.
84. Poirier J, Hess M, May PC, Finch CE: Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res Mol Brain Res (1991) 11(2):97-106.
85. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM: Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem (2000) 275(41):31567-31572
86. Pasinetti GM, Hassler M, Stone D, Finch CE: Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions. Synapse (1999) 31(4):278-284.
87. Vincent B, Smith JD: Astrocytes down-regulate neuronal β-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner. Eur J Neurosci (2001) 14(2):256-266.
88. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE: Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem (1994) 269(38):23403-23406.
89. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT: Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J Biol Chem (1995) 270(16):9039-9042.
90. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2000) 97(6):2892-2897. Demonstration of apoE isoform-dependent amyloid deposition and neuritic degeneration in mutant human APP transgenic mice.
91. V717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (1999) 96(26):15233-15238. Demonstration that apoE is essential for amyloid deposition in mutant human APP transgenic mice.
92. Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G, Schwartz AL: Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA (1995) 92(21):9480-9484.
93. Hartman RE, Wozniak DF, Nardi A, Olney JW, Sartorius L, Holtzman DM: Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp Neurol (2001) 170(2):326-344.
94. Xu PT, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu HL, Popko B, Sullivan P, Maeda N, Saunders AM, Roses AD, Gilbert JR: Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: Human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis (1996) 3(3):229-245.
95. Aoki K, Uchihara T, Sanjo N, Nakamura A, Ikeda K, Tsuchiya K, Wakayama Y: Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke (2003) 34(4):875-880.
96. Dupont-Wallois L, Soulie C, Sergeant N, Wavrant-de Wrieze N, Chartier-Harlin MC, Delacourte A, Caillet-Boudin ML: ApoE synthesis in human neuroblastoma cells. Neurobiol Dis (1997) 4(5):356-364.
97. Ferreira S, Dupire MJ, Delacourte A, Najib J, Caillet-Boudin ML: Synthesis and regulation of apolipoprotein E during the differentiation of human neuronal precursor NT2/D1 cells into postmitotic neurons. Exp Neurol (2000) 166(2):415-421.
98. Ramos MC, Matias S, Artiga MJ, Pozueta J, Sastre I, Valdivieso F, Bullido MJ: Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter. NeuroReport (2005) 16(9):1027-1030
99. Soulie C, Mitchell V, Dupont-Wallois L, Chartier-Harlin MC, Beauvillain JC, Delacourte A, Caillet-Boudin ML: Synthesis of apolipoprotein E (apoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and apoE. Neurosci Lett (1999) 265(2):147-150.
100. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW: Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA (2001) 98(15):8838-8843. First demonstration that apoE fragments present in AD brains induce neurofibrillary tangle-like intracellular inclusions in neurons.
101. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH et al: Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA (2003) 100(19):10966-10971. Demonstration that apoE4 fragment causes AD-like neurodegeneration and behavioral deficits in transgenic mice.
102. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW et al: Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 24(10):2527-2534. Demonstration that apoE4 proteolysis is neuron-specific and age- and brain-region-dependent in transgenic mice.
103. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y: Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci USA (2005) 102(51):18694-18699. Demonstration that apoE4 fragments escape the secretory pathway, enter the cytosol, and interact with mitochondria, leading to mitochondrial dysfunction.
104. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F: Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol (2000) 156(3):951-964.
105. Tesseur I, Van Dorpe J, Bruynseels K, Bronfman F, Sciot R, Van Lommel A, Van Leuven F: Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am J Pathol (2000) 157(5)11495-1510.
106. Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y: Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: Modulation by zinc. J Biol Chem (2004) 279(43):44795-44801.
107. Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW: Apolipoprotein E4 potentiates amyloid β peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem (2002) 277(24):21821-21828. First demonstration that apoE4 potentiates Aβ-caused lysosomal leakage and apoptosis in neuronal cultures.
108. Roses AD: Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis (1997) 4(3-4):170-185.
109. Raffai RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton MF, Fazio S, Weisgraber KH: Hepatocyte-derived apoE is more effective than non-hepatocyte-derived apoE in remnant lipoprotein clearance. J Biol Chem (2003) 278(13):11670-11675.
110. Selkoe DJ: Clearing the brain's amyloid cobwebs. Neuron (2001) 32(2):177-180.
111. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA (1993) 90(17):8098-8102.
112. Cho HS, Hyman BT, Greenberg SM, Rebeck GW: Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation. J Neuropathol Exp Neurol (2001) 60(4):342-349
113. Moir RD, Atwood CS, Romano DM, Laurans MH, Huang X, Bush AI, Smith JD, Tanzi RE: Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations. Biochemistry (1999) 38(14):4595-4603.
114. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ: Isoform-specific effect of apolipoprotein E on cell survival and β-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci (1998) 18(1):195-204.
115. Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM: Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2005) 102(4):1211-1216. Demonstration that lentiviral-mediated gene delivery of human apoE alters brain Aβ burden in an isoform-specific manner in hAPP transgenic mice.
116. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM: Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat Med (2004) 10(7):719-726. Demonstration that apoE is required for astrocyte clearance of β-amyloid peptides.
117. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, Paul SM et al: Cognitive impairment in PDAPP mice depends on apoE and ACT-catalyzed amyloid formation. Neurobiol Aging (2004) 25(9):1153-1167.
118. Lesuisse C, Xu G, Anderson J, Wong M, Jankowsky J, Holtz G, Gonzalez V, Wong PC, Price DL, Tang F, Wagner S et al: Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum Mol Genet (2001) 10(22):2525-2537.
119. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT: Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 47(6):739-747.
120. Selkoe DJ: Alzheimer's disease: A central role for amyloid. J Neuropathol Exp Neurol (1994) 53(5):438-447.
121. Yankner BA: Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron (1996) 16(5):921-932.
122. Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL: Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science (1989) 245(4916):417-420.
123. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW: Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA (1993) 90(17):7951-7955.
124. Estus S, Tucker HM, van Rooyen C, Wight S, Brigham EF, Wogulis M, Rydel RE: Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J Neurosci (1997) 17(20):7736-7745.
125. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML: Caspase-2 mediates neuronal cell death induced by β-amyloid. J Neurosci (2000) 20(4):1386-1392.
126. Uetsuki T, Takemoto K, Nishimura I, Okamoto M, Niinobe M, Momoi T, Miura M, Yoshikawa K: Activation of neuronal easpase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J Neurosci (1999) 19(16):6955-6964.
127. LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J: Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem (1999) 274(33):23426-23436.
128. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature (2000) 403(6765):98-103.
129. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA: β-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem (2001) 77(1):157-164.
130. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME: β-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci (2001) 21(19):7551-7560.
131. LaDu MJ, Lukens JR, Reardon CA, Getz GS: Association of human, rat, and rabbit apolipoprotein E with β-amyloid. J Neurosci Res (1997) 49(1):9-18.
132. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 106(12):1489-1499.
133. Pillot T, Goethals M, Najib J, Labeur C, Lins L, Chambaz J, Brasseur R, Vandekerckhove J, Rosseneu M: β-Amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: Relevance to Alzheimer's disease. J Neurochem (1999) 72(1):230-237.
134. Drouet B, Fifre A, Pincon-Raymond M, Vandekerckhove J, Rosseneu M, Gueant JL, Chambaz J, Pillot T: ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-β peptide. J Neurochem (2001) 76(1):117-127.
135. Tolar M, Marques MA, Harmony JA, Crutcher KA: Neurotoxicity of the 22 KDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci (1997) 17(15):5678-5686.
136. Tolar M, Keller JN, Chan S, Mattson MP, Marques MA, Crutcher KA: Truncated apolipoprotein E (apoE) causes increased intracellular calcium and may mediate apoE neurotoxicity. J Neurosci (1999) 19(16):7100-7110.
137. Ljungberg MC, Dayanandan R, Asuni A, Rupniak TH, Anderton BH, Lovestone S: Truncated apoE forms tangle-like structures in a neuronal cell line. NeuroReport (2002) 13(6):867-870.
138. Frankel AD, Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell (1988) 55(6):1189-1193.
139. Green M, Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell (1988) 55(6):1179-1188
140. Tanaka M, Vedhachalam C, Sakamoto T, Dhanasekaran P, Phillips MC, Lund-Katz S, Saito H: Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4. Biochemistry (2006) 45(13):4240-4247.
141. Chou CY, Jen WP, Hsieh YH, Shiao MS, Chang GG: Structural and functional variations in human apolipoprotein E3 and E4. J Biol Chem (2006) 281(19):13333-13344.
142. Beisiegel U, Weber W, Havinga JR, Ihrke G, Hui DY, Wernette-Hammond ME, Turck CW, Innerarity TL, Mahley RW: Apolipoprotein E-binding proteins isolated from dog and human liver. Arteriosclerosis (1988) 8(3):288-297.
143. Hamilton RL, Wong JS, Guo LS, Krisans S, Havel RJ: Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res (1990) 31(9):1589-1603.
144. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM: Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol (2002) 156(6):1051-1063.
145. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 307(5713):1282-1288.
146. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E: Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease. J Cell Biol (1998) 143(3):777-794.
147. Miller KE, Sheetz MP: Axonal mitochondrial transport and potential are correlated. J Cell Sci (2004) 117(Pt 13):2791-2804.
148. Rintoul GL, Filiano AJ, Brocard JB, Kress GJ, Reynolds IJ: Glutamate decreases mitochondrial size and movement in primary forebrain neurons. J Neurosci (2003) 23(21):7881-7888.
149. Li Z, Okamoto K, Hayashi Y, Sheng M: The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell (2004) 119(6):873-887. Demonstration of the importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses in neuronal cultures.
150. Morris RL, Hollenbeck PJ: The regulation of bidirectional mitochondrial transport is coordinated with axonal outgrowth. J Cell Sci (1993) 104(Pt 3):917-927.
151. van Rossum D, Hanisch UK: Cytoskeletal dynamics in dendritic spines: Direct modulation by glutamate receptors? Trends Neurosci (1999) 22(7):290-295.
152. Shepherd GM, Harris KM. Three-dimensional structure and composition of CA3→CA1 axons in rat hippocampal slices: Implications for presynaptic connectivity and compartmentalization. J Neurosci (1998) 18(20):8300-8310
153. Reynolds IJ, Malaiyandi LM, Coash M, Rintoul GL: Mitochondrial trafficking in neurons: A key variable in neurodegeneration? J Bioenerg Biomembr (2004) 36(4):283-286.
154. Verstreken P, Ly CV, Venken KJ, Koh TW, Zhou Y, Bellen HJ: Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron (2005) 47(3):365-378.
155. Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD Jr, Davis RE: Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci (1999) 893:176-191.
156. Trimmer PA, Borland MK: Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal (2005) 7(9-10):1101-1109.
157. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, Kitamura S, Namekata K, Miki T, Ohta S: Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophys Res Commun (2000) 273(1):192-196.
158. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S et al: Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 21(9):3017-3023.
159. Gibson GE, Haroutunian V, Zhang H, Park LC, Shi Q, Lesser M, Mohs RC, Sheu RK, Blass JP: Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 48(3):297-303.
160. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA (2004) 101(1):284-289. Demonstration of functional brain abnormalities in young adults at genetic risk for late onset AD by a PET scan.
161. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J: Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA (2005) 102(23):8299-8302.
162. Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, Wagenpfeil S, Minoshima S, Schwaiger M, Kurz A: Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology (2005) 64(1):102-107.
163. Small SA: Age-related memory decline. Current concepts and future directions. Arch Neurol (2001) 58(3):360-364.
164. Small SA, Chawla MK, Buonocore M, Rapp PR, Barnes CA: Imaging correlates of brain function in monkeys and rats isolates a hippocampal subregion differentially vulnerable to aging. Proc Natl Acad Sci USA (2004) 101(18):7181-7186.
165. Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Sorbi S, Pupi A: Metabolic interaction between apoE genotype and onset age in Alzheimer's disease: Implications for brain reserve. J Neurol Neurosurg Psychiatry (2005) 76(1):15-23.
166. Mosconi L, Nacmias B, Sorbi S, De Cristofaro MT, Fayazz M, Tedde A, Bracco L, Herholz K, Pupi A: Brain metabolic decreases related to the dose of the apoE ε4 allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 75(3):370-376.
167. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B et al: MCI conversion to dementia and the apoE genotype: A prediction Study with FDG-PET. Neurology (2004) 63(12):2332-2340.
168. Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Herholz K, Pupi A: Age and apoE genotype interaction in Alzheimer's disease: An FDG-PET study. Psychiatry Res (2004) 130(2):141-151.
169. Hirono N, Hashimoto M, Yasuda M, Ishii K, Sakamoto S, Kazui H, Mon E: The effect of apoE ε4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology (2002) 58(5):743-750.
170. Scarmeas N, Habeck CG, Hilton J, Anderson KE, Flynn J, Park A, Stern Y: apoE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry (2005) 76(10):1440-1444.
171. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006): in press. First demonstration that rosiglitazone, an insulin sensitizer and mitogenesis stimulator, might be beneficial for AD patients without apoE4.
172. Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, Dong LM, Jakes R, Alberts MJ, Gilbert JR, Han S-H et al: Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 125(2):163-171.
173. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD: Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer disease. Proc Natl Acad Sci USA (1994) 91(23):11183-11186.
174. Nathan BP, Chang KC, Bellosta S, Brisch E, Ge N, Mahley RW, Pitas RE: The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem (1995) 270(34):19791-19799.
175. DeMattos RB, Curtiss LK, Williams DL: A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem (1998) 273(7):4206-4212.
176. DeMattos RB, Rudel LL, Williams DL: Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J Lipid Res (2001) 42(6):976-987.
177. Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM: Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem (1996) 271(47):30121-30125.
178. Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, Fagan AM, Holtzman DM: Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: Astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci (1998) 18(9):3261-3272.
179. Bellosta S, Nathan BP, Orth M, Dong LM, Mahley RW, Pitas RE: Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem (1995) 270(45):27063-27071.
180. Qiu Z, Hyman BT, Rebeck GW: Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J Biol Chem (2004) 279(33):34948-34956.
181. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ: Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 94(2):860-869.
182. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature (1994) 372(6501):92-94.
183. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV: Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J Neurochem (1997) 69(5):1995-2004.
184. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B: Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol (1994) 145(5):1030-1035.
185. V717F transgenic mice. Acta Neuropathol (2000) 100(5):451-458.
186. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet (1996) 14(1):55-61.
187. 1-42-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res (2002) 924(1):90-97.
188. Mazur-Kolecka B, Frackowiak J, Kowal D, Krzeslowska J, Dickson D: Oxidative protein damage in cells engaged in β-amyloidosis is related to apoE genotype. NeuroReport (2002) 13(4):465-468.
189. Herz J, Beffert U: Apolipoprotein E receptors: Linking brain development and Alzheimer's disease. Nat Rev Neurosci (2000) 1(1):51-58.
190. Qiu Z, Crutcher KA, Hyman BT, Rebeck GW: ApoE isoforms affect neuronal N-methyl-D-aspartate calcium responses and toxicity via receptor-mediated processes. Neuroscience (2003) 122(2):291-303.
191. Hoe HS, Harris DC, Rebeck GW: Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem (2005) 93(1):145-155.
192. 40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis (2001) 3(1):23-30.
193. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M: Apolipoprotein E (apoE) isoform-dependent lipid release from astrocytes prepared from human apoE3 and apoE4 knock-in mice. J Biol Chem (2002) 277(33):29919-29926.
194. Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Geiz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ: Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem (1999) 274(42):30001-30007.